TRex Bio Misses by $9.37: Quarterly Loss of $10.06 Per Share

TRex Bio (NASDAQ:TRXB) reported a quarterly loss of $10.06 per share on Friday, missing analysts' consensus estimate of a $0.69 loss by $9.37, according to Zacks. The gap is the story here — this isn't a marginal miss; it's more than 14 times the expected loss.

The market's reaction was comparatively muted. TRXB shares traded down $0.43 on Friday to close at $13.67, on volume of 62,668 shares against an average of 106,799. The stock has moved between a twelve-month low of $12.50 and a twelve-month high of $16.56.

In plain words: a massive earnings miss, but only a modest share-price penalty.

What do the analysts say?

Coverage of TRXB picked up sharply in early November, and the ratings skew positive despite the miss:

• JPMorgan Chase & Co. initiated on Tuesday, November 3, with an "overweight" rating and a $20.00 price target.
• Cantor Fitzgerald assumed coverage the same day, November 3, with an "overweight" rating.
• Wedbush started coverage Monday, November 2, with an "outperform" rating and a $30.00 price objective.
• Zacks Research initiated November 3 with a "hold" rating.
• Evercore initiated November 3 with a "strong-buy" rating.

Aggregating the street: one analyst rates TRXB Strong Buy, four rate it Buy, and one rates it Hold. MarketBeat.com puts the average rating at "Buy" with an average price target of $29.67 — more than double Friday's $13.67 close.

Takeaway: the sell side sees value the market hasn't priced in, at least on paper.

Who is buying the stock?

There's a notable insider transaction on file. Major shareholder Alexandria Venture Investments purchased 178,571 shares on Tuesday, October 13, at an average price of $14.00 per share — a total outlay of $2,499,994.00, disclosed in a Securities and Exchange Commission filing.

The purchase lifted the holder's stake by 15.29%, to 1,346,501 shares valued at $18,851,014. A ~$2.5 million insider buy at $14.00 — above where the stock trades now — is a concrete signal someone close to the company is adding, not trimming.

One-line read: an insider bought at a higher price than the market is currently offering.

What does TRex Bio actually do?

TRex Bio is a clinical-stage biopharmaceutical company built around tissue Treg biology — the study of regulatory T cells ("Tregs," immune cells that help control inflammation). The company's premise is that Tregs in human tissue aren't just passive suppressors of inflammation but active orchestrators of tissue immune balance and repair. Its pipeline aims to develop immunoregulatory medicines that restore immune balance and promote tissue repair for patients with autoimmune and inflammatory diseases.

That clinical-stage label matters for reading the earnings number. Pre-revenue biotechs routinely post large per-share losses tied to accounting items, so a single quarter's EPS gap doesn't map neatly onto pipeline progress.

The scoreboard: a $10.06 per-share loss, a $0.43 share-price dip, five bullish analyst calls, one hold, and a $2.5 million insider purchase.